434 related articles for article (PubMed ID: 25428222)
21. Successful immune tolerance induction with low-dose coagulation factor VIII in a patient with hemophilia A from a developing country.
Ay Y; Ersin T; Yesim O; Hilkay KT; Dilek I; Gulcihan O; Ahmet K
Blood Coagul Fibrinolysis; 2016 Sep; 27(6):729-31. PubMed ID: 26484639
[TBL] [Abstract][Full Text] [Related]
22. [Hemophilia--present and past].
Terada H
Nihon Rinsho; 2008 Mar; 66(3):591-9. PubMed ID: 18330030
[TBL] [Abstract][Full Text] [Related]
23. Bypassing agent prophylaxis in people with hemophilia A or B with inhibitors.
Chai-Adisaksopha C; Nevitt SJ; Simpson ML; Janbain M; Konkle BA
Cochrane Database Syst Rev; 2017 Sep; 9(9):CD011441. PubMed ID: 28944952
[TBL] [Abstract][Full Text] [Related]
24. Estimating the potential cost of a high dose immune tolerance induction (ITI) therapy relative to the cost of a combined therapy of a low dose ITI therapy with bypassing agent prophylaxis.
Kenet G; Oladapo A; Epstein JD; Thompson C; Novack A; Nugent DJ
Haemophilia; 2017 Sep; 23(5):e394-e402. PubMed ID: 28641362
[TBL] [Abstract][Full Text] [Related]
25. The importance of inhibitor eradication in clinically complicated hemophilia A patients.
Oldenburg J; Young G; Santagostino E; Escuriola Ettingshausen C
Expert Rev Hematol; 2018 Nov; 11(11):857-862. PubMed ID: 30286680
[TBL] [Abstract][Full Text] [Related]
26. Prophylaxis in 10 patients with severe haemophilia A and inhibitor: different approaches for different clinical situations.
Jiménez-Yuste V; Alvarez MT; Martín-Salces M; Quintana M; Rodriguez-Merchan C; Lopez-Cabarcos C; Velasco F; Hernández-Navarro F
Haemophilia; 2009 Jan; 15(1):203-9. PubMed ID: 19149850
[TBL] [Abstract][Full Text] [Related]
27. Prophylaxis with recombinant factor VIIa for the management of bleeding episodes during immune tolerance treatment in a boy with severe haemophilia A and high-response inhibitors.
Blatny J; Kohlerova S; Zapletal O; Fiamoli V; Penka M; Smith O
Haemophilia; 2008 Sep; 14(5):1140-2. PubMed ID: 18540894
[No Abstract] [Full Text] [Related]
28. How I use bypassing therapy for prophylaxis in patients with hemophilia A and inhibitors.
Leissinger CA; Singleton T; Kruse-Jarres R
Blood; 2015 Jul; 126(2):153-9. PubMed ID: 25827834
[TBL] [Abstract][Full Text] [Related]
29. Prevention of bleeding in hemophilia patients with high-titer inhibitors.
Leissinger CA; Konkle BA; Antunes SV
Expert Rev Hematol; 2015 Jun; 8(3):375-82. PubMed ID: 25937074
[TBL] [Abstract][Full Text] [Related]
30. Early eradication of factor VIII inhibitor in patients with congenital hemophilia A by immune tolerance induction with a high dose of immunoglobulin.
Mizoguchi Y; Furue A; Kagawa R; Chijimatsu I; Tomioka K; Shimomura M; Imanaka Y; Nishimura S; Saito S; Miki M; Ono A; Konishi N; Kawaguchi H; Kobayashi M
Int J Hematol; 2016 Apr; 103(4):473-7. PubMed ID: 26830966
[TBL] [Abstract][Full Text] [Related]
31. Hemophilia and inhibitors: current treatment options and potential new therapeutic approaches.
Meeks SL; Batsuli G
Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):657-662. PubMed ID: 27913543
[TBL] [Abstract][Full Text] [Related]
32. Prevention of inhibitor development in hemophilia A in 2016. A glimpse into the future?
Franchini M; Lippi G
Thromb Res; 2016 Dec; 148():96-100. PubMed ID: 27816852
[TBL] [Abstract][Full Text] [Related]
33. Prophylactic treatment in hemophilic patients with inhibitors.
Haya S
Blood Coagul Fibrinolysis; 2019 Sep; 30(1S Suppl 1):S14-S18. PubMed ID: 31517711
[TBL] [Abstract][Full Text] [Related]
34. Prophylactic bypassing agent use before and during immune tolerance induction in patients with haemophilia A and inhibitors to FVIII.
Carpenter SL; Khair K; Gringeri A; Valentino LA
Haemophilia; 2018 Jul; 24(4):570-577. PubMed ID: 29901839
[TBL] [Abstract][Full Text] [Related]
35. Challenges of the management of severe hemophilia A with inhibitors: two case reports emphasizing the potential interest of a high-purity human Factor VIII/von Willebrand factor concentrate and individually tailored prophylaxis guided by thrombin-generation test.
Mathieu S; Crampe C; Dargaud Y; Lavigne-Lissalde G; Escuriola-Ettingshausen C; Tardy B; Meley R; Thouvenin S; Stephan JL; Berger C
Blood Coagul Fibrinolysis; 2015 Dec; 26(8):940-5. PubMed ID: 26517064
[TBL] [Abstract][Full Text] [Related]
36. Successful immune tolerance induction with high-dose coagulation factor VIII and intravenous immunoglobulins in a patient with congenital hemophilia and high-titer inhibitor of coagulation factor VIII despite unfavorable prognosis for the therapy.
Kubisz P; Plamenová I; Hollý P; Stasko J
Med Sci Monit; 2009 Jun; 15(6):CS105-11. PubMed ID: 19488019
[TBL] [Abstract][Full Text] [Related]
37. The diagnosis and management of factor VIII and IX inhibitors: a guideline from the United Kingdom Haemophilia Centre Doctors Organisation.
Hay CR; Brown S; Collins PW; Keeling DM; Liesner R
Br J Haematol; 2006 Jun; 133(6):591-605. PubMed ID: 16704433
[TBL] [Abstract][Full Text] [Related]
38. Treatment of patients with haemophilia and inhibitory antibodies.
Giangrande PL
Indian J Pediatr; 2003 Aug; 70(8):655-9. PubMed ID: 14510087
[TBL] [Abstract][Full Text] [Related]
39. Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors.
Key NS; Aledort LM; Beardsley D; Cooper HA; Davignon G; Ewenstein BM; Gilchrist GS; Gill JC; Glader B; Hoots WK; Kisker CT; Lusher JM; Rosenfield CG; Shapiro AD; Smith H; Taft E
Thromb Haemost; 1998 Dec; 80(6):912-8. PubMed ID: 9869160
[TBL] [Abstract][Full Text] [Related]
40. Factor VIII alloantibody inhibitors: cost analysis of immune tolerance induction vs. prophylaxis and on-demand with bypass treatment.
Earnshaw SR; Graham CN; McDade CL; Spears JB; Kessler CM
Haemophilia; 2015 May; 21(3):310-319. PubMed ID: 25688580
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]